Gilead's lung cancer bid for Trodelvy hits wall, but HIV studies deliver better news

FierceBiotechGalmed acquires Colospan in $4.5M deal as it eyes $6B GI dx market

BioPharma DiveMerck, Gilead report mixed outcomes in key lung cancer, HIV studies

Endpoints NewsA different approach to lowering healthcare costs

CellmRNA 3′ UTRs chaperone intrinsically disordered regions to control protein activity

Clinical OMICsBeyond the Genome: Five Emerging Leaders in Epigenetics Diagnostics

BioPharma DiveStealthy startup Treeline plans a reverse merger

10x Genomics Blog10x Genomics Acquires Proteintech Genomics to Expand Single-Cell Proteomics Portfolio - citybiz

Endpoints NewsHow K Health moved AI chatbots into hospitals

10x Genomics News10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group - BioSpace

Endpoints NewsLilly offers up to $1B for Alzheimer's drug; Bial cuts failed Parkinson's drug

Endpoints NewsTrodelvy misses in lung cancer, but Gilead and Merck have an HIV success

FierceBiotechADA: AZ’s oral GLP-1 shows ‘competitive efficacy’ in phase 2, setting stage for pivotal program